Salute e Benessere

AB Science reports its revenues for the year 2023 and provides an update on its…

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)First complete bone marrow response in an acute myeloid leukemia patient in its AB8939 Phase I/II clinical trialNew clinical...
Nasdaq GlobeNewswire
15/05/2024

The Adoption of Multimodal Imaging Market to Boom, Integration of PET/CT…

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029. Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029. Browse in-depth TOC on the Multimodal Imaging Market 127 – Tables 102 – Figures 341 – Pages Multimodal Imaging Market Report Scope Multimodal imaging has emerged as a pivotal tool in modern healthcare,...
PR Newswire
15/05/2024

Groupe Casino: AVAILABILITY OF INFORMATION RELATED TO THE ORDINARY AND…

CASINO, GUICHARD-PERRACHONA Frenchsociété anonyme(joint-stock company) with share capital of €375,740,444.29 Registered office: 1, Cours Antoine Guichard 42000 Saint-Etienne, France Registered with the Saint-Etienne Trade and Companies Registry Availability of information related to the Ordinary and Extraordinary Annual General Meeting of 11 June 2024 CASINO, GUICHARD-PERRACHON's shareholders are invited to participate in the Ordinary and Extraordinary Shareholders' Meeting...
Nasdaq GlobeNewswire
15/05/2024

PHAXIAM provides Business and Financial Update for the First Quarter of 2024

PHAXIAM provides Business and Financial Updatefor the First Quarter of 2024Webinar(in French) today, May 15, 2024, at 6.00 pm CESTAccelerated clinical efforts to roll-out PHAXIAM's strategy in order to create a global phage-therapy leader in high-value indicationsCash and cash equivalents of €5.8 million, as of March 31, 2024 Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical...
Nasdaq GlobeNewswire
15/05/2024

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early…

Pelareorep, an intravenously delivered immunotherapeutic agent being developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), is gaining momentum as a potential treatment for multiple cancers, especially breast cancer and pancreatic cancer. In late 2022, the FDA granted pelareorep Fast Track Designation for treating pancreatic cancer, following promising clinical results. Now Oncolytics has recently announced a preliminary collaboration with the Global Coalition for Adaptive Research…
PR Newswire
15/05/2024

Osteotec announces Lisa Watts as National Sales Manager of new spine division

The launch of the spine division marks a strategic shift for Osteotec, diversifying its offering to customers beyond its existing focus on orthopaedic extremities. The launch of the spine division marks a strategic shift for Osteotec, diversifying its offering to customers beyond its existing focus on orthopaedic extremities. The new offering will provide surgeons with the exceptional sales and operational support Osteotec is known for, while providing new opportunities for growth in...
PR Newswire
15/05/2024

Bioinformatics Market to Be Worth $31.71 Billion by 2031 - Exclusive Report by…

Genomic data is incredibly voluminous, as it involves information about thousands of genes across multiple individuals or species. Genomes contain several elements, such as genes, regulatory regions, non-coding RNAs, and repetitive sequences. Analyzing and interpreting these components is difficult without proper tools and software. Moreover, the data generated from multi-omics fields, including transcriptomics, metabolomics, and proteomics, needs bioinformatic tools and software to collect…
PR Newswire
15/05/2024

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase…

Primary results of the Scemblix ®ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali ® * NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion...
Nasdaq GlobeNewswire
15/05/2024

Alvotech S.A. Annual General Meeting to be held June 7, 2024

The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. Reference is made to the attached document with regard to the final agenda.Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website:...
Nasdaq GlobeNewswire
15/05/2024

Mural Health Named "Most Innovative Start-up" at the 2024 Citeline Awards

"This innovative approach helps trial participants and sponsors and should help expand access to trials, thereby increasing cohort diversity." - Citeline Awards judges "This innovative approach helps trial participants and sponsors and should help expand access to trials, thereby increasing cohort diversity." - Citeline Awards judges Mural Link empowers sites and sponsors globally with exceptional engagement, streamlined operations, and better results to help transformative…
PR Newswire
15/05/2024

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

"We are delighted to participate in ERA and look forward to engaging with the leaders in the renal space," said Richard Philipson, Chief Medical Officer at Calliditas. "We are especially excited to be in Stockholm, where Calliditas is headquartered and where we developed the first treatment specifically designed for IgA nephropathy, to present analyses that highlight the continued opportunity for our treatment to address the significant unmet need in this rare disease."…
PR Newswire
15/05/2024

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Participation in the annual general meeting at the venue Participation in the annual general meeting at the venue A shareholder who wishes to participate in the annual general meeting at the venue in person or represented by a proxy must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on7 June 2024, and (ii) no later than11 June 2024give notice by post to Calliditas Therapeutics AB (publ), Annual General Meeting...
PR Newswire
15/05/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 15 May 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
Nasdaq GlobeNewswire
15/05/2024

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect…

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' websiteir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for...
Nasdaq GlobeNewswire
15/05/2024

Making Waves: Experience Abu Dhabi x Vilebrequin Launch a Swimwear Capsule…

The house's iconic sea turtle motif encounters Abu Dhabi's palm trees, creating a joyful design reminiscent of beautiful moments in the sun with loved ones. Manufactured with respect to the environment, these crafted pieces are tailored from high-grade recycled polyamide and highlight a commitment to sustainability. The house's iconic sea turtle motif encountersAbu Dhabi'spalm trees, creating a joyful design reminiscent of beautiful moments in the sun with loved ones. Manufactured with...
PR Newswire
15/05/2024

Making Waves: Experience Abu Dhabi x Vilebrequin Launch a Swimwear Capsule…

The house's iconic sea turtle motif encounters Abu Dhabi's palm trees, creating a joyful design reminiscent of beautiful moments in the sun with loved ones. Manufactured with respect to the environment, these crafted pieces are tailored from high-grade recycled polyamide and highlight a commitment to sustainability. The house's iconic sea turtle motif encountersAbu Dhabi'spalm trees, creating a joyful design reminiscent of beautiful moments in the sun with loved ones. Manufactured with...
PR Newswire
15/05/2024

Center for Treatment of Paralysis and Reconstructive Nerve Surgery at Hackensack…

The Center for Treatment of Paralysis and Reconstructive Nerve Surgery (CPRNS), in partnership with The Institute for Advanced Reconstruction, and under the expert leadership of renowned surgeons Matthew Kaufman, M.D., FACS, and Andrew Elkwood, M.D., FACS, stands at the forefront of global medical innovation. At this world class center specializing in reconstructive surgery for a variety of peripheral nerve disorders, the surgeons have pioneered surgical treatments for debilitating conditions…
PR Newswire
15/05/2024

Major shareholder announcement – BlackRock, Inc.

ANNOUNCEMENT NO. 266Major shareholder announcementMajor shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 13 May 2024, decreased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to below 10%, and that the holding thus is below the 10 per cent limit in section 38 of...
Nasdaq GlobeNewswire
15/05/2024

Digital Personalized Nutrition Market 2024 Exclusive Report with Accurate…

Digital personalized nutrition describes the practice of using electronic resources to create unique plans for each person's diet and nutritional needs. The global digital personalized nutrition market is anticipated to have significant expansion in the coming years, propelled by technological progress. Biomarker analysis, microbiome analysis, and DNA sequencing in saliva, blood, and urine are all examples of diagnostic tools formed by these technical advancements. The expansion of wearable…
PR Newswire
15/05/2024

Philips announces exchange ratio for 2023 dividend

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2023 is 1 new common share for every 29.2684 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 9, 10 and 13, 2024, of EUR 24.8481 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of...
Nasdaq GlobeNewswire
15/05/2024

Prosthetic Heart Valve Market to Reach $30.3 billion, Globally, by 2035 at 11.1%…

Request Sample of the Report on Prosthetic Heart Valve Market Forecast 2035 - https://www.alliedmarketresearch.com/request-sample/2176 Request Sample of the Report on Prosthetic Heart Valve Market Forecast 2035 -https://www.alliedmarketresearch.com/request-sample/2176 Prime determinants of growth Surge in prevalence of structural heart valve diseases, increase in demand for minimally invasive procedures, rise in number of product approvals, and upsurge in geriatric population...
PR Newswire
15/05/2024

Photocure ASA: Results for the first quarter of 2024

Photocure reported total group revenues of NOK 118.0 million in the first quarter of 2024 (NOK 106.2 million) and EBITDA* of NOK 7.9 million (NOK -1.2 million), driven by a combination of unit volume and price increases and a benefit from foreign exchange. Hexvix®/Cysview® revenues ended at NOK 116.8 million in the quarter (Q1 2023: NOK 105.9 million). EBIT was NOK 0.7 million (NOK -7.7 million) and the cash balance at the end of the period was NOK 258.3 million. Photocure reported total…
PR Newswire
15/05/2024

MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in…

The LANDMARK study showed that the performance of Myval THV series in terms of safety and effectiveness was non-inferior to the contemporary THV series (24.7% vs. 27.0%, occurrence of primary composite endpoint which is composite of deaths, stroke, major bleeding, acute kidney injury, major vascular complications, moderate or severe valve regurgitation, and the need for new permanent pacemaker implantation as per the third Valve Academic Research Consortium consensus) with no difference in the…
PR Newswire
15/05/2024

Implantica publishes Interim Report January - March 2024 (Q1)

Significant events in the first quarter of 2024 Significant events in the first quarter of 2024 Significant events after the end of the period Financial summary first quarter 2024 Telephone conference Implantica will hold a teleconference on15 May 2024at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast ...
PR Newswire
15/05/2024
Altri  Comunicati